Edwards Lifesciences Corporation $EW Stock Sold by Fisher Asset Management LLC

Fisher Asset Management LLC lowered its position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 8.3% in the third quarter, HoldingsChannel reports. The fund owned 80,503 shares of the medical research company’s stock after selling 7,266 shares during the quarter. Fisher Asset Management LLC’s holdings in Edwards Lifesciences were worth $6,949,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. BlackRock Inc. purchased a new position in Edwards Lifesciences during the second quarter worth approximately $5,318,092,000. Varma Mutual Pension Insurance Co acquired a new stake in Edwards Lifesciences in the second quarter valued at approximately $11,168,000. Assenagon Asset Management S.A. grew its holdings in Edwards Lifesciences by 50.0% in the third quarter. Assenagon Asset Management S.A. now owns 2,719,271 shares of the medical research company’s stock valued at $234,727,000 after purchasing an additional 906,345 shares during the period. Conway Capital Management Inc. acquired a new stake in Edwards Lifesciences in the second quarter valued at approximately $954,000. Finally, Commerce Bank purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $3,121,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Royal Bank Of Canada increased their target price on Edwards Lifesciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. Robert W. Baird raised shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating and set a $116.00 price target for the company in a report on Thursday, November 5th. Wells Fargo & Company reissued an “overweight” rating and issued a $113.00 price target (up from $100.00) on shares of Edwards Lifesciences in a report on Thursday, November 5th. Mizuho set a $120.00 price objective on shares of Edwards Lifesciences in a research report on Thursday, November 5th. Finally, Weiss Ratings raised shares of Edwards Lifesciences from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, November 9th. Twenty-three research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $109.56.

View Our Latest Stock Report on Edwards Lifesciences

Edwards Lifesciences Trading Up 0.0%

EW stock opened at $107.16 on Monday. Edwards Lifesciences Corporation has a 12-month low of $74.66 and a 12-month high of $107.69. The business’s 50-day moving average is $90.42 and its 200 day moving average is $86.32. The company has a current ratio of 4.60, a quick ratio of 3.86 and a debt-to-equity ratio of 0.05. The stock has a market cap of $61.62 billion, a price-to-earnings ratio of 60.54, a PEG ratio of 2.86 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its earnings results on Wednesday, November 4th. The medical research company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.06. The business had revenue of $1.72 billion during the quarter, compared to analysts’ expectations of $1.68 billion. Edwards Lifesciences had a return on equity of 16.06% and a net margin of 15.30%. The business’s revenue was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.67 earnings per share. On average, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3.01 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the transaction, the senior vice president directly owned 14,868 shares of the company’s stock, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 48,900 shares of the firm’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $103.05, for a total value of $5,039,145.00. Following the completion of the transaction, the vice president owned 22,798 shares in the company, valued at $2,349,333.90. The trade was a 68.20% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 53,945 shares of company stock valued at $5,498,306. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

(Free Report)

Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.

Featured Stories

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.